For psoriatic arthritis, four small-molecule drugs were all superior to placebo and comparable with adalimumab. Upadacitinib and deucravacitinib consistently were in the top two across efficacy ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the ...

In a meta-analysis of 37 studies, patients receiving infliximab were switched to adalimumab or certolizumab ... is the first of the newer small-molecule agents for the treatment of chronic ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time ...

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when ...

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the TNF-alpha inhibitors infliximab (Janssen Biotech/Merck ...

One of the most common current treatments for severe rheumatoid arthritis is a monoclonal antibody called adalimumab. This treatment inhibits an immune signaling molecule called tumor necrosis ...

While adalimumab biosimilars are just now launching in the United States, there have been options available in Europe and elsewhere for years. According to Amgen, there will be 2 tiers of pricing ...